Skip to main content
. Author manuscript; available in PMC: 2009 Aug 31.
Published in final edited form as: Ann Rheum Dis. 2007 Sep 17;67(6):829–834. doi: 10.1136/ard.2007.077594

Table 3.

Time-to-seizure occurrence by multivariable proportional hazard regression analysis in patients in the LUMINA cohort*

Variable HR (95% CI) p Value
Younger age, years 1.04 (1.00 to 1.08) 0.0304
SLAM-R 1.10 (1.04 to 1.15) 0.0004
Mucocutaneous manifestations 0.34 (0.16 to 0.41) 0.0039
Hydroxychloroquine use 0.35 (0.15 to 0.80) 0.0131

LUMINA, LUpus in MInorities: NAture versus Nurture.

*

Adjusted for gender, ethnicity, marital status, disease duration, damage accrual (seizures excluded), disease manifestations (musculoskeletal, psychosis and renal damage) and medications (cyclophosphamide, average dose of glucocorticoids).

Systemic Lupus Activity Measure-Revised at baseline (secures excluded).

For alternative analyses, please refer to text.